ストックスクリーナーアプリを入手
7.09
0.00%
0.00
アフターアワーズ：
7.10
0.010
+0.14%
前日終値:
$7.09
開ける：
$7.09
24時間の取引高:
325.53K
Relative Volume:
1.32
時価総額：
$454.83M
収益：
-
当期純損益:
$-106.19M
株価収益率:
-3.9124
EPS:
-1.8122
ネットキャッシュフロー:
$-85.19M
1週間 パフォーマンス:
+4.73%
1か月 パフォーマンス:
+19.36%
6か月 パフォーマンス:
+11.65%
1年 パフォーマンス:
+27.29%
1日の値動き範囲:
$7.00
$7.20
1週間の範囲:
$6.59
$7.20
52週間の値動き範囲:
$4.345
$7.4799
Aura Biosciences Inc Stock (AURA) Company Profile
Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.09 | 454.83M | 0 | -106.19M | -85.19M | -1.8122 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-26 | 再開されました | Evercore ISI | Outperform |
| 2025-05-28 | 再開されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-07-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Aura Biosciences Inc (AURA) 最新ニュース
Is Aura Biosciences (AURA) stock outpacing its medical peers this year? - MSN
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
Aura Biosciences, Inc. (AURA) just flashed golden cross signal: Do you buy? - MSN
Aura Biosciences, Inc. (AURA) Recently Triggered a Golden Cross Signal: Is It Time to Invest? - Bitget
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
AURA Should I Buy - Intellectia AI
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Quarterly Recap: Does Aura Biosciences Inc outperform in volatile markets2026 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Aura Biosciences (NASDAQ:AURA) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Research Analysts Offer Predictions for AURA FY2030 Earnings - Defense World
Wall Street experts forecast a potential 201.49% increase for Aura Biosciences (AURA): Key information you need to know - Bitget
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know - sharewise.com
FY2030 Earnings Forecast for AURA Issued By HC Wainwright - MarketBeat
H.C. Wainwright reiterates Aura Biosciences stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Aura Biosciences stock rating at buy - Investing.com
Aura Biosciences Reports 2025 Results, Advances Bel-Sar Pipeline - tipranks.com
Aura Biosciences (NASDAQ:AURA) Earns Buy Rating from HC Wainwright - MarketBeat
Aura Biosciences Reports 2025 Financial Results and Advances Phase 3 CoMpass Trial for Choroidal Melanoma - Minichart
Aura Biosciences 2025 Annual Report: Advancing Bel-sar for Ocular and Urologic Oncology with Late-Stage Clinical Development - Minichart
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aura Biosciences 10-K: $0 Revenue, $(106.2)M Net Loss - TradingView — Track All Markets
Aura Biosciences (NASDAQ:AURA) Issues Earnings Results - MarketBeat
Bel-sar pipeline data and cash risks in Aura Biosciences (NASDAQ: AURA) 10-K - Stock Titan
Aura Biosciences 2025 net loss widens as R&D costs rise - TradingView — Track All Markets
Aura Biosciences (NASDAQ: AURA) details 2025 loss, cash runway to Q1 2027 and bel-sar trial timelines - Stock Titan
BRIEF-Aura Biosciences FY Operating Expenses USD 112.791 Million - TradingView
Aura says eye melanoma Phase 3 enrollment now points to 2027 data - Stock Titan
Aura Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
(AURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings Update: Is Aura Biosciences Inc exposed to currency risksForecast Cut & Advanced Technical Signal Analysis - baoquankhu1.vn
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Hold" by Brokerages - MarketBeat
Notice of Successful Bidder Filed by Clearside Biomedical, Inc. - marketscreener.com
Is Aura Biosciences (AURA) outperforming other medical stocks this year? - MSN
What makes Aura Biosciences (AURA) a new buy stock - msn.com
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Bear Alert: Is Aura Biosciences Inc stock undervalued right nowMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Aura Biosciences (AURA) to Release Earnings on Monday - MarketBeat
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Latest AURA NewsAura Biosciences to Participate at the 11th... - Stock Titan
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline - Yahoo Finance
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
AURA: Phase 3 ocular oncology drug nears enrollment completion, with pivotal data expected in Q4 2027 - TradingView
Aura Biosciences Inc (AURA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):